Otsuka Holdings operates in pharmaceuticals, nutraceuticals, and consumer products. The business activity of the company includes providing healthcare solutions in the areas of the nervous system, oncology, cardiovascular system, respiratory system, infectious disease, and others. The company engages in the research and development of functional foods and beverages, such as electrolyte drinks, nutritional foods, soy snacks, and dietary foods.

Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry. Jazz Pharmaceuticals focuses on identifying, developing, and commercializing products for neurology and psychiatry primarily in the United States. Its products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Cystadane for the treatment of homocystinuria, an inherited metabolic disease; and Antizol to treat ethylene glycol and methanol poisoning. Its late-stage product candidates comprise Luvox CR, an extended-release formulation of fluvoxamine, a selective serotonin reuptake inhibitor, which is used for the treatment of obsessive-compulsive disorder and social anxiety disorder; and JZP-6, a liquid dosage form of sodium oxybate in Xyrem, for the treatment of fibromyalgia syndrome.

Grünenthal GmbH engages in the research and development of pharmaceutical products. It specializes in pain, gout, and inflammation. The company was founded by Hermann Wirtz in 1946 and is headquartered in Aachen, Germany.

Part of Jazz Pharmaceuticals Plc, GW Research Ltd. is a company headquartered in Cambridge, UK. The firm engages in researching and developing biotechnology. It was founded in 1995.

Provides pharmaceutical research and development services

Beijing Harmony Health Medical Diagnostics Co., Ltd. is a Chinese private company located in Beijing. The firm provides medical laboratory services. It was founded in 2010.

Jinan Tonglu Pharmaceutical Technology Development Co., Ltd., established on 2006-04-12, Business scope includes general items:Medical Research and Experimental Development;Engineering and Technology Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Chemical product sales(No licensed chemical products)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:pharmaceutical production;Import and export;Technology Import and Export(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results)

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Hangzhou LONGi Biotechnology Co., Ltd., established on 2004-06-09, Business scope includes technology development,technical consulting,Technical Services,Achievement transfer:Biotechnology,Biological product;Production:Food Safety Rapid Testing Products,medical instruments6840Clinical laboratory analysis instruments and in vitro diagnostic reagents;Sales:Biological raw materials for non-medical use,experimental reagent(Removal of hazardous chemicals and precursor chemicals),Experimental consumables,second,Class III Medical Devices,Experimental equipment,Primary Edible Agricultural Products(except food,medicine);Import and export(law,Except for items prohibited by administrative regulations,law,Projects that are restricted by administrative regulations can only be operated after obtaining a license).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Hale BioPharma Ventures, LLC engages in formation and development of biotechnology and specialty pharmaceutical companies. The company was founded in 2005 and is based in Encinitas, California

Sinopharm Group Guorui Pharmaceutical Co., Ltd., established on 1998-08-05, The business scope includes freeze-dried powder injection,powder injection(Contains cephalosporins),small volume injection,tablet,hard capsule,API,Sterile API,Psychotropic drugs,inhalant,Healthy food,Daily Chemicals,Production and sales of chemical intermediates,technology transfer,Technical Services,technology development,technical consulting:material transfer:Enterprise Marketing Planning:Business Consulting:market research:Economic Information Consulting:Branding:Acquisition of agricultural and sideline products.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

CEA is a French government-funded technological research organisation. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world. The CEA is the French Alternative Energies and Atomic Energy Commission (Commissariat à l'énergie atomique et aux énergies alternatives). It is a public body established in October 1945 by General de Gaulle. A leader in research, development and innovation, the CEA mission statement has two main objectives: To become the leading technological research organization in Europe and to ensure that the nuclear deterrent remains effective in the future. The CEA is active in four main areas: low-carbon energies, defense and security, information technologies and health technologies. In each of these fields, the CEA maintains a cross-disciplinary culture of engineers and researchers, building on the synergies between fundamental and technological research. The total CEA workforce consisted of 15 838 employees. Across the whole of the CEA (including both civilian and military research), there were 1556 PhD students and 293 post-docs. The CEA is based in ten research centers in France, each specializing in specific fields. The laboratories are located in the Paris region, the Rhône-Alpes, the Rhône valley, the Provence-Alpes-Côte d'Azur region, Aquitaine, Central France and Burgundy. The CEA benefits from the strong regional identities of these laboratories and the partnerships forged with other research centers, local authorities and universities.

Janssen Pharmaceutica is a pharmaceutical company headquartered in Beerse, Belgium and owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen. In 1961, Janssen Pharmaceutica was purchased by New Jersey-based American corporation Johnson & Johnson, and became part of Johnson & Johnson Pharmaceutical Research and Development (J&J PRD), now renamed to Janssen Research and Development (JRD), which conducts research and development activities related to a wide range of human medical disorders, including mental illness, neurological disorders, anaesthesia and analgesia, gastrointestinal disorders, fungal infection, HIV/AIDS, allergies and cancer. Janssen and Ortho-McNeil Pharmaceutical have been placed in the Ortho-McNeil-Janssen group within Johnson & Johnson Company.

Venturepharma, Inc. manufactures pharmaceutical products. It offers VP discovery, API development and outsourcing, biopharmaceuticals discovery, RX and OTC. The firm provides products for oncology, CNS, dermnova, diabetes, cardiovascular, respiration and vaccine. The company was founded in 1998 and is headquartered in Haidian, China.

Hefei Hehe Medical Technology Co., Ltd., established on 2017-08-04, The business scope includes medical equipment,two,Three types of research and development,Production,Sales;Technical development of biological products,Technical Services;Self-operated and agent import and export business of various commodities and technologies(Except for goods and technologies restricted and prohibited by the state).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

BIAL’s mission is to discover, develop and provide new therapeutic solutions within the area of Health. Today, BIAL is an innovative international pharmaceutical company with products available in more than 55 countries. The company is committed to making a contribution to improve human health and quality of life for people from all over the world. “Caring for your Health” is the Group’s motto, and strategic areas are Innovation, Internationalisation and Quality. Strongly committed to therapeutic innovation, and consistently investing more than 20% of its annual revenue in Research and Development (R&D), BIAL has established an ambitious R&D programme. Key focus areas for the Group are the neurosciences and cardiovascular. BIAL has launched eslicarbazepine acetate, an epilepsy drug, already available in the US and in several European countries. BIAL has also developed a Parkinson’s disease compound, opicapone, also commercialized in Europe. The company expects to introduce new medicines to the market over the next few years, strengthening its international presence.

NeurogesX, Inc., a biopharmaceutical company, engages in the development and commercialization of novel pain management therapies. It primarily focuses on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP), and painful diabetic neuropathy (PDN). The company's lead product candidate NGX-4010 is a dermal patch containing capsaicin, a selective TRPV1 agonist designed to manage pain associated with peripheral neuropathic pain conditions. It is also developing NGX-1998, a non-patch liquid formulation of synthetic capsaicin, and an opioid analgesic for use in managing pain associated with other chronic pain conditions, such as cancer pain. The company was founded in 1998 as Advanced Analgesics, Inc. and changed its name to NeurogesX, Inc. in 2000. NeurogesX is headquartered in San Mateo, California.

Orexo is a pharmaceutical company based in Uppsala, Sweden initially financed with venture capital provided by HealthCap. The company was founded in 1995 and their first product Diabact UBT, a breath test for diagnosing the causative agent of stomach ulcers (Helicobacter pylori), was introduced in 2000. In 2003, the company adopted the name Orexo and in 2005 the company was listed on the Stockholm Stock Exchange.On March 29, 2019 a U.S. jury rejected a claim by Sweden’s Orexo AB that two generic opioid-addiction treatments created by Teva Pharmaceutical Industries Ltd. infringed a patent for Orexo’s biggest drug, Zubsolv.

Hubei Huazhong Pharmaceutical Co. Ltd. (doing business as Huazhong Pharmaceutical Co. Ltd.) is a company headquartered in Xiangfan, China and ultimately controlled by the Government of China, specializing in pharmaceutical preparations.